Patents Represented by Attorney Joseph A. Jones
  • Patent number: 5783590
    Abstract: 6-Heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz?cd!indoles are provided which are useful in modifying the function of serotonin in mammals.
    Type: Grant
    Filed: June 20, 1994
    Date of Patent: July 21, 1998
    Assignee: Eli Lilly and Company
    Inventors: Richard N. Booher, Michael E. Flaugh, David E. Lawhorn, Michael J. Martinelli, Charles J. Paget, Jr., John M. Schaus
  • Patent number: 5719287
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of their use.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 17, 1998
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Kaldor, Marlys Hammond
  • Patent number: 5658788
    Abstract: The present invention provides derivatives of tissue plasminogen activator that lack the Finger, Growth Factor and Kringle 1 domains and comprise a Kringle 2 domain that is monoglycosylated at a site other than that of t-PA. Using recombinant DNA techniques, an alternate glycosylation sequence is provided within the Kringle 2 domain of these t-PA derivatives. This alternate glycosylation consensus sequence, as well as the glycosylation consensus sequence within the Serine Protease domain, is glycosylated upon the expression and secretion of these molecules from eucaryotic host cells. Thus, a homogeneous population of diglycosylated t-PA derivatives that lack the Finger, Growth Factor and Kringle 1 domains is produced.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 19, 1997
    Assignee: Eli Lilly and Company
    Inventors: David T. Berg, Brian W. Grinnell
  • Patent number: 5654320
    Abstract: Indazolecarboxamides are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 5, 1997
    Assignee: Eli Lilly and Company
    Inventors: John T. Catlow, Michael J. Martinelli, John M. Schaus, Steven Swanson, Dennis C. Thompson
  • Patent number: 5635197
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in preventing the development of prostatic cancer, or preventing or treating the metastasis to bone of prostatic cancer.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: June 3, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Blake L. Neubauer
  • Patent number: 5629007
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in preventing the development of prostatic cancer, or preventing or treating the metastasis to bone of prostatic cancer.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: May 13, 1997
    Assignee: ELi Lilly and Company
    Inventors: James E. Audia, Blake L. Neubauer
  • Patent number: 5627196
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 6, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, David J. Hibschman, Joseph H. Krushinski, Jr., Thomas E. Mabry, Jeffrey S. Nissen, Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
  • Patent number: 5625065
    Abstract: A stereoselective process for forming compounds related to 4-endotropanamine through the reactive amination of a corresponding ketone with a triacyloxy borohydride.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: April 29, 1997
    Assignee: Eli Lilly and Company
    Inventor: John M. McGill, III
  • Patent number: 5622961
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco
  • Patent number: 5622962
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco
  • Patent number: 5620968
    Abstract: The invention provides compounds of the formula: ##STR1## wherein the variables are hereinbelow described; and salts thereof. Also, pharmaceutical formulations and methods for treating bacterial infections in man or other animals using the above compounds are disclosed.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: April 15, 1997
    Assignee: Eli Lilly and Company
    Inventor: Ho-Shen Lin
  • Patent number: 5614523
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Joseph H. Krushinski, Jr., Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
  • Patent number: 5606048
    Abstract: A stereoselective glycosylation process for preparing beta- and alpha-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides by reacting a concentrated alpha- or beta-anomer enriched 2 -deoxy-2,2-difluorocarbohydrate or 2-deoxy-2 -fluorocarbohydrate with at least a molar equivalent of a nucleobase derivative in a high boiling inert solvent.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: February 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: Ta-Sen Chou, Laurie M. Poteet, Douglas P. Kjell
  • Patent number: 5594019
    Abstract: 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd]indoles are provided which are useful in modifying the function of serotonin in mammals.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: January 14, 1997
    Assignee: Eli Lilly and Company
    Inventors: Richard N. Booher, Michael E. Flaugh, David E. Lawhorn, Charles J. Paget, Jr., John M. Schaus
  • Patent number: 5594028
    Abstract: This invention provides certain sulfonamide derivatives, their pharmaceutical formulations, and their use in the treatment of susceptible neoplasms in mammals.
    Type: Grant
    Filed: November 21, 1994
    Date of Patent: January 14, 1997
    Assignee: Eli Lilly and Company
    Inventors: Richard W. Harper, J. Jeffry Howbert, Gerald A. Poore, Brent J. Rieder, Eddie V. P. Tao, James A. Aikins
  • Patent number: 5591714
    Abstract: New N-alkyl and N-acyl derivatives of A82846A, A82846B, A82846C and PA-42867-A are provided. The new glycopeptide derivatives are useful for the treatment of susceptible bacterial infections, especially infections due to Gram-positive microorganisms.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: January 7, 1997
    Assignee: Eli Lilly and Company
    Inventors: Ramakrishnan Nagarajan, Amelia A. Schabel
  • Patent number: 5578713
    Abstract: The disclosure relates to a new process for the synthesis of the macrolide antibiotic dirithromycin in crystalline form. The process is carried out in a single reaction vessel whereby an acetal dissolved in acetonitrile, in the presence of an acid catalyst, is hydrolyzed to the related hemiacetal which then reacts directly with erythromycylamine to form crystalline dirithromycin.
    Type: Grant
    Filed: July 20, 1993
    Date of Patent: November 26, 1996
    Assignee: Eli Lilly and Company
    Inventor: John M. McGill, III
  • Patent number: 5576321
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 19, 1996
    Assignee: Eli Lilly and Company
    Inventors: Joseph H. Krushinski, Jr., Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson
  • Patent number: 5574160
    Abstract: A 1-pot process for preparing 10b-methyl-3-oxo-benzo[f] quinolines.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 12, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Perry C. Heath, Leland O. Weigel
  • Patent number: 5571942
    Abstract: The present invention provides novel ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes which exhibit binding activity at the serotonin 1A receptor.
    Type: Grant
    Filed: August 22, 1995
    Date of Patent: November 5, 1996
    Assignee: Eli Lilly and Company
    Inventors: Craig S. Hoechstetter, Diane L. Huser, John M. Schaus, Robert D. Titus